CENTRAL TRUST Co Buys New Stake in AstraZeneca PLC $AZNCF

CENTRAL TRUST Co purchased a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) during the first quarter, according to its most recent filing with the SEC. The fund purchased 8,830 shares of the company’s stock, valued at approximately $1,741,000.

Several other hedge funds have also bought and sold shares of AZNCF. Hughes Financial Services LLC purchased a new position in shares of AstraZeneca during the fourth quarter valued at about $34,000. Bell Investment Advisors Inc purchased a new stake in shares of AstraZeneca in the first quarter worth about $39,000. Fairscale Capital LLC purchased a new stake in shares of AstraZeneca in the fourth quarter worth about $37,000. Aventus Investment Advisors Inc. bought a new position in AstraZeneca during the first quarter valued at approximately $46,000. Finally, Mascoma Wealth Management LLC bought a new position in AstraZeneca during the fourth quarter valued at approximately $46,000. Hedge funds and other institutional investors own 40.87% of the company’s stock.

AstraZeneca Stock Performance

OTCMKTS AZNCF opened at $187.10 on Thursday. AstraZeneca PLC has a 1-year low of $122.26 and a 1-year high of $195.00. The business has a 50 day simple moving average of $187.10 and a two-hundred day simple moving average of $186.19.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.